 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H17FN3O2S |
| Molar mass | 406.46 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MK-4409 is an experimental drug which acts as a potent and selective inhibitor of the enzymefatty acid amide hydrolase (FAAH), with an IC50 of 11 nM, and bothanalgesic andantiinflammatory effects in animal studies. It was studied for the treatment ofneuropathic pain and progressed to early stage humanclinical trials by 2009.[1][2]
